Lifevantage Corporation Common Stock (Delaware) (LFVN)
LFVN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/849146/000119312526371257/0001193125-26-371257-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | LFVN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000849146 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | COLORADO |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $182.6M |
| Net income | $5.1M |
| Operating income | $6.1M |
| Net margin | 2.8% |
| Operating margin | 3.3% |
| Revenue growth | -20.1% |
| Cash | $14.9M |
| Total assets | $62.1M |
| P/E (computed) | 11.9× |
| P/S (computed) | 0.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $13.7M cash; operating cash flow $3.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 12,682,221 (2026-11-06); 12,701,187 a year earlier; 12,713,887 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Salt Lake City, Utah, United States | PCAOB Form AP 2026-09-04 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $196K, sold $472K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-09-30 | $37.1M | -$196K | $533K | $13.7M | No debt tags | $172.1M | 10-Q 2026-11-09 |
| Q4 2026 2026-06-30 | $42.4M | $1.3M | $4.8M | $14.9M | No debt tags | $182.6M | 10-K 2026-08-27 |
| Q3 2026 2026-03-31 | $43.7M | $1.4M | $5.0M | $12.5M | No debt tags | $195.3M | 10-Q 2026-05-06 |
| Q2 2026 2025-12-31 | $48.9M | $276K | $2.8M | $10.2M | No debt tags | $210.0M | 10-Q 2026-02-04 |
| Q1 2026 2025-09-30 | $47.6M | $2.2M | -$2.3M | $13.1M | No debt tags | $228.9M | 10-Q 2026-11-09 |
| Q4 2025 2025-06-30 | $55.1M | $2.0M | $1.0M | $20.2M | No debt tags | $228.5M | 10-K 2026-08-27 |
| Q3 2025 2025-03-31 | $58.4M | $3.5M | $2.2M | $22.5M | No debt tags | $222.3M | 10-Q 2026-05-06 |
| Q2 2025 2024-12-31 | $67.8M | $2.5M | $9.2M | $21.6M | No debt tags | $212.2M | 10-Q 2026-02-04 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-03-10 |
| Latest annual report | 10-K | 2026-08-27 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-09-18 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.8% |
| 1 month | -16.5% |
| 3 months | -23.4% |
| Year to date | -19.3% |
| 1 year | -23.2% |
| From 52-week high | -53.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MAIA | MAIA Biotechnology Inc. | $1.01 | +1.00% | $62.4M |
| ACRV | Acrivon Therapeutics Inc. | $1.46 | +0.69% | $62.6M |
| FBIO | Fortress Biotech Inc. | $1.71 | -9.04% | $57.7M |
| BOLD | Boundless Bio Inc. | $2.41 | -3.60% | $56.9M |
| XBIT | XBiotech Inc. | $1.85 | -5.37% | $56.4M |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $2.88 | -4.32% | $56.0M |
| SPRO | Spero Therapeutics Inc. | $0.9464 | -5.35% | $55.1M |
| VRCA | Verrica Pharmaceuticals Inc. | $3.20 | -10.11% | $55.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier